Roche and Genmab reach second collaboration milestone  

Second Genmab antibody achieves proof of concept in Roche collaboration

Danish biotech company Genmab and international pharma concern Roche have announced that Genmab has achieved the second collaborative milestone of proof of concept with a human antibody generated by Genmab. This is the second antibody programme in the alliance to reach this vital stage.


Under the agreement, Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products, and could obtain rights to develop products under certain circumstances. If all goals are reached, the value of the collaboration to Genmab could be as high as USD 100 million plus royalties.


Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and aims to assemble a portfolio of new therapeutic products arising from research into the human genome. Genmab is headquartered in Copenhagen and has operations in Holland and the US.


Link > Genmab

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×